A Randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
A Randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma. // EJC Paediatric Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2772610X26000449?dgcid=rss_sd_all
A Randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma. EJC Paediatric Oncology. https://www.sciencedirect.com/science/article/pii/S2772610X26000449?dgcid=rss_sd_all
“A Randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma.” EJC Paediatric Oncology.
@article{article146696,
title = {A Randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma},
journal = {EJC Paediatric Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2772610X26000449?dgcid=rss_sd_all}
}